CSWI Form 4: Armes Disposes Shares; Performance Rights & RSUs Remain
Rhea-AI Filing Summary
CSW Industrials insider sales by Chairman/CEO under a 10b5-1 plan. Joseph B. Armes, who serves as Chairman, President and CEO, reported multiple open-market dispositions of common stock on 08/15/2025 under a previously established 10b5-1 trading plan (adopted September 12, 2024). The Form 4 lists a series of sales totaling 1,150 shares sold across multiple price ranges (weighted-average prices shown per lot from about $254.94 to $268.65), reducing his direct common stock holding from 63,432 to 62,522 shares reported after the transactions. He also reports 3,219 shares held indirectly by an ESOP and outstanding performance rights and restricted stock units convertible to a total of 66,719 potential shares (sum of listed performance rights and RSUs). Several performance cycles and vesting conditions are described, including relative TSR comparisons to the Russell 2000 and time-based CEO succession triggers for RSUs.
Positive
- Sales executed under a 10b5-1 plan, indicating trades were pre-planned and provide an affirmative defense to insider trading allegations
- Comprehensive disclosure of weighted-average price ranges and undertaking to provide per-price breakdowns on request
- Significant outstanding incentive awards (performance rights and RSUs) maintain executive alignment with shareholder performance
Negative
- Reduction in direct ownership from 63,432 to 62,522 shares after reported sales
- Material potential dilution from 66,719 contingent shares (performance rights and RSUs) that may convert to common stock if vesting conditions are met
Insights
TL;DR: CEO sold a small portion of holdings under a pre-established 10b5-1 plan; substantial contingent awards remain outstanding.
The reported sales were executed under a documented 10b5-1 plan, which provides an affirmative defense to insider trading accusations and signals the trades were pre-planned rather than opportunistic. The total reduction in direct common shares is modest relative to the combination of directly owned shares and contingent awards. The filing also details material long-term incentive instruments (performance rights tied to relative TSR and restricted stock units conditioned on CEO succession), which maintain significant potential dilution and ongoing alignment incentives. From a governance viewpoint, the disclosure is routine and properly annotated with weighted-average price ranges and vesting schedules.
TL;DR: Transaction is routine insider selling; outstanding equity awards preserve upside exposure.
The sales occurred across multiple tranches at prices ranging roughly from the mid-$250s to high-$260s per share and reduced reported direct ownership by about 910 shares (from 63,432 to 62,522 reported after each sale sequence). Importantly, the reporting person retains thousands of performance rights and RSUs that could convert into common stock subject to performance and time conditions, representing potential future dilution and management incentive alignment. The 10b5-1 plan date is disclosed, supporting transaction transparency. Overall, this Form 4 does not indicate unusual or material governance concerns but is relevant for tracking insider liquidity and remaining incentive exposure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 90 | $255.45 | $23K |
| Sale | Common Stock | 51 | $256.67 | $13K |
| Sale | Common Stock | 160 | $257.86 | $41K |
| Sale | Common Stock | 266 | $258.85 | $69K |
| Sale | Common Stock | 191 | $259.88 | $50K |
| Sale | Common Stock | 51 | $260.90 | $13K |
| Sale | Common Stock | 128 | $262.09 | $34K |
| Sale | Common Stock | 40 | $262.94 | $11K |
| Sale | Common Stock | 10 | $266.70 | $3K |
| Sale | Common Stock | 13 | $268.43 | $3K |
| holding | Performance Rights | -- | -- | -- |
| holding | Performance Rights | -- | -- | -- |
| holding | Performance Rights | -- | -- | -- |
| holding | Performance Rights | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on September 12, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.94 to $255.94, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.22 to $257.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.36 to $258.34, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.39 to $259.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.41 to $260.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.47 to $261.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.48 to $262.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.68 to $263.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.50 to $267.08, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.33 to $268.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2025 and ending on March 31, 2028 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2023 and ending on March 31, 2026 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest in two equal amounts, at a rate between 0% and 200%, during two performance cycles beginning April 1, 2021 ending on each of March 31, 2026 and 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.
FAQ
What did CSWI insider Joseph B. Armes sell on 08/15/2025?
Are there outstanding equity awards for CSWI reported on this Form 4?
Were these sales discretionary or part of a pre-set plan?
What performance conditions apply to the performance rights?
